/
ERAS
$17.86-$0.72 (-3.88%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$6.5B
350M shares
52-week range
$1.33 – $24.28
72% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-1.66
Erasca, Inc. Common Stock
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
www.erasca.com- Employees
- 103
- IPO / List date
- Jul 16, 2021
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds ERAS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,398,869 | $22.6M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ERAS yet.
